Table 1.
(Abstract 7) Clinical biomarkers of response to anti-PD-1 and progression free survival. This Table 1 belongs to Abstract 7
| Univariate | Multivariate* | |||
|---|---|---|---|---|
| Types of Melanoma (cutaneous, mucosal, uveal) | Types of Melanoma (cutaneous, mucosal, uveal) | |||
| Crude HR (95%CI) | P | Adjusted HR (95%CI) | P | |
| ECOG performance status | ||||
| 0 | 1 | 1 | ||
| 1 | 2.13 (1.09–4.16) | 0.026 | 2.67 (1.30–5.52) | 0.008 |
| ≥ 2 | 3.08 (1.56–6.05) | 0.001 | 2.21 (1.06–4.63) | 0.035 |
| Stages of metastasis | ||||
| 1a-1b | 1 | 1 | ||
| 1c | 1.88 (1.04–3.38) | 0.036 | 1.80 (0.95–3.41) | 0.074 |
| 1d | 3.18 (1.66–6.08) | < 0.0001 | 2.92 (1.38–6.18) | 0.005 |
| LDH serum | ||||
| Normal | 1 | 1 | ||
| High | 2.32 (1.34–4.01) | 0.003 | 2.09 (1.16–3.75) | 0.014 |
HR, Hazard Ratio; CI, Confidence Interval
* the estimates are adjusted for gender, age, ECOG PS, stage of metastasis and LDH levels